The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects.
BACKGROUND
The role of inflammation in the pathogenesis and progression of atherosclerosis has been increasingly discussed. Although the seroepidemiological studies have suggested a relationship between Helicobacter pylori (H. pylori) infection and atherosclerosis; the issue is still controversial. It is well known that abnormal lipid profil is related to atherosclerosis and the measurement of carotid-intima media thickness (CIMT) is one of the surrogate marker of atherosclerosis. The serum concentration of high-density lipoprotein (HDL-C) has been known to have an inverse correlation with the development of atherosclerosis. Paraoxonase-1 (PON1) is a major anti-atherosclerotic component of HDL-C. PON1 activity is related to lipid peroxidation and prospective cardiovascular risk. The aim of this study was to investigate CIMT and serum PON1 activities along with lipid parameters in H. pylori positive and negative subjects.


METHODS
Thirty H. pylori positive subjects and thirty-one negative subjects were enrolled. H. pylori infection was diagnosed by the presence of positivity of stool H. pylori antigen test or Carbon 14 labeled urea breath test. Serum PON1 activity was measured spectrophotometrically. Traditional cardiovascular risk factors were investigated and laboratory analysis included measurement of serum triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C). We assessed CIMT by high-resolution ultrasound of both common carotid arteries.


RESULTS
We found that the mean and maximum values of right and overall CIMT in H. pylori positive subjects were significantly thicker than those of H. pylori negative subjects. There was no significant differences in serum HDL-C, LDL-C, TC levels and TC/HDL-C ratios between two groups. Serum TG levels of H. pylori positive subjects were significantly higher than those of H. pylori negative subjects (p = 0.014). We found that PON1 activities were significantly lower in H. pylori positive subjects compared with negative subjects. No significantly correlation was observed between PON1 and CIMT values.


CONCLUSIONS
There is an increase in CIMT values in patients with H. pylori positive compared to H. pylori negative subjects. PON1 activity decrease significantly in H. pylori positive subjects. However, an association between PON1 and CIMT was not found. These data indicated that H. pylori may have a role in atherosclerotic processes, however, further studies are needed to evaluate the exact mechanisms.
Akbas
Halide S
HS
Akdeniz University Faculty of Medicine, Department of Biochemistry, Antalya, Turkey. halideakbas@akdeniz.edu.tr
Basyigit
Sebahat
S
Suleymanlar
Inci
I
Kemaloglu
Didem
D
Koc
Serkan
S
Davran
Fatih
F
Demir
Ibrahim
I
Suleymanlar
Gultekin
G
D000328:Adult; D043303:Aryldialkylphosphatase / Q000097:blood*; D050197:Atherosclerosis / Q000097:blood / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D002340:Carotid Artery Diseases / Q000097:blood / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000473:pathology; D017536:Carotid Artery, Common / Q000000981:diagnostic imaging / Q000473:pathology*; D042241:Early Diagnosis; D005260:Female; D016481:Helicobacter Infections / Q000097:blood / Q000150:complications* / Q000473:pathology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012720:Severity of Illness Index; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000473:pathology*; D018608:Ultrasonography, Doppler
D015415:Biomarkers; D008055:Lipids; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human
Eur J Clin Invest. 2000 Jan;30(1):4-10
10619995
Circulation. 2002 Jul 9;106(2):184-90
12105156
Lancet. 1994 Jul 16;344(8916):146
7912762
Atherosclerosis. 2007 Sep;194(1):175-81
16942773
Ann Rheum Dis. 2003 Sep;62(9):842-5
12922956
Atheroscler Suppl. 2003 Mar;4(1):31-6
12714035
Atherosclerosis. 1995 Jun;115(2):243-53
7661883
Clin Chem. 1972 Jun;18(6):499-502
4337382
Circulation. 1998 Sep 1;98(9):845-50
9738638
Clin Biochem. 2009 Sep;42(13-14):1394-400
19538950
N Engl J Med. 1994 May 5;330(18):1267-71
8145781
Lipids Health Dis. 2009 Dec 23;8:59
20030806
Atherosclerosis. 2008 Jan;196(1):270-274
17125774
J Stroke Cerebrovasc Dis. 2008 Mar-Apr;17(2):86-94
18346651
Free Radic Biol Med. 2003 Mar 15;34(6):774-84
12633754
Curr Opin Lipidol. 2004 Aug;15(4):399-404
15243212
Br Heart J. 1994 May;71(5):437-9
8011406
Clin Biochem. 2004 May;37(5):388-94
15087255
J Cardiovasc Risk. 2002 Feb;9(1):1-6
11984211
N Engl J Med. 1999 Jan 7;340(1):14-22
9878640
Clin Rev Allergy Immunol. 2009 Aug;37(1):44-8
18985284
Atherosclerosis. 1999 Jan;142(1):207-10
9920523
Curr Opin Lipidol. 2004 Jun;15(3):261-7
15166781
Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1335-7
10563551
Lancet. 1997 Aug 9;350(9075):430-6
9259669
Angiology. 2005 Jul-Aug;56(4):451-8
16079929
JAMA. 1995 Oct 4;274(13):1064-6
7563460
Clin Exp Hypertens. 2010 Jan;32(1):13-20
20144068
Int J Clin Pract. 2007 May;61(5):810-4
17343667
BMJ. 1998 Apr 11;316(7138):1130-2
9552950
Arterioscler Thromb Vasc Biol. 2001 Mar;21(3):427-32
11231924
Indian J Med Res. 2009 Oct;130(4):361-8
19942738
Circulation. 1997 Sep 2;96(5):1432-7
9315528